Pfizer Inc. announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas.
The drug more than doubled the time patients with pancreatic neuroendocrine tumors lived without disease progression compared with patients treated with placebo, according to study findings that will be presented Saturday at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in Orlando, Fla.
“This trial advances our understanding of the use of novel targeted therapies in a patient population with limited treatment options,” said Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer’s oncology business unit.
Pfizer is seeking regulatory approval for Sutent as a pancreatic cancer treatment in the U.S., Europe and Canada.
to read the full article and find out more go to businesswire.com